Elevated cholesteryl ester transfer protein concentration is associated with an increased risk for cardiovascular disease in women, but not in men, with Type 2 diabetes: The Hoorn study

Diabetic Medicine

Volumn 24, Issue 2, 2007, Pages 117-123

  Alssema, M ^a   Dekker, J M ^a   Kuivenhoven, J A ^b   Nijpels, G ^a   Teerlink, T ^a   Scheffer, P G ^a   Diamant, M ^a   Stehouwer, C D A ^a,c   Bouter, L M ^a   Heine, R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Intima media thickness of the carotid artery; Lipoproteins; Type 2 diabetes

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN;

ADULT; AGED; AMPUTATION; ANGINA PECTORIS; ANKLE BRACHIAL INDEX; ARTERY DIAMETER; ARTERY SURGERY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAUCASIAN; CEREBROVASCULAR DISEASE; CLAUDICATION; COHORT ANALYSIS; COMMON CAROTID ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEART INFARCTION; HUMAN; IMMUNOASSAY; IMPAIRED GLUCOSE TOLERANCE; INTIMA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SELF REPORT; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS; ULTRASOUND;

AGED; BODY MASS INDEX; CAROTID ARTERY DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; NETHERLANDS; PREVALENCE; RISK FACTORS; TUNICA INTIMA;

EID: 33846610627     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02033.x     Document Type: Article

References (39)

1. Morton RE, Zilversmit DB. Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. J Biol Chem 1983; 258: 11751-11757.
2. Kastelein JJ. The future of lipid-lowering therapy: the big picture. Neth J Med 2003; 61: 35-39.
3. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105: 2159-2165.
4. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-167.
5. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004; 45: 1967-1974.
6. Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004; 110: 1418-1423.
7. de Grooth GJ, Smilde TJ, Van Wissen S, Klerkx AH, Zwinderman AH, Fruchart JC et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004; 173: 261-267.
8. Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004; 34: 21-28.
9. Chaaba R, Hammami S, Attia N, Smaoui M, Masmoudi AS, Mahjoub S. Association of plasma cholesteryl ester transfer protein activity and polymorphism with coronary artery disease extent in Tunisian type II diabetic patients. Clin Biochem 2005; 38: 373-378.
10. Mooy JM, Grootenhuis PA, de Vries H, Kostens PJ, Popp-Snyders C, Bouter LM et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298-305.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
12. Spijkerman AM, Adriaanse MC, Dekker JM, Nypels G, Stehouwer CD, Bouter LM et al. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care 2002; 25: 1784-1789.
13. Henry RM, Kostense PJ, Spijkerman AM, Dekker JM, Nypels G, Heine RJ et al. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 2003; 107: 2089-2095.
14. van Wijk JP, Buirma R, van Tol A, Halkes CJ, De Jaegere PP, Plokker HW et al. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis 2005; 178: 147-155.
15. Ocke MC, Bueno-de-Mesquita HB, Goddijn HE, Jansen A, Pols MA, van Staveren WA et al. The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups. Int J Epidemiol 1997; 26: S37-S48.
16. Scheffer PG, Bakker SJ, Heine RJ, Teerlink T. Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography. Clin Chem 1997; 43: 1904-1912.
17. Bos G, Scheffer PG, Vieira D, Dekker JM, Nypels G, Diamant M et al. The relationship of lipoprotein lipase activity and LDL size is dependent on glucose metabolism in an elderly population: the Hoorn Study. Diabetes Care 2004; 27: 796-798.
18. Niemeijer-Kanters SD, Dallinga-Thie GM, Ruijter-Heijstek FC, Algra A, Erkelens DW, Banga JD et al. Effect of intensive lipidlowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis 2001; 156: 209-216.
19. Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003; 12: 111-123.
20. Prineas RJ. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston, MA: Year Book Medical Publishers, 1982.
21. Kors JA, van Herpen G, Wu J, Zhang Z, Prineas RJ, van Bemmel JH. Validation of a new computer program for Minnesota coding. J Electrocardiol 1996; 29: 83-88.
22. Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. Geneva: WHO Press, 1982.
23. Guerin M, Le Goff W, Lassel TS, van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21: 282-288.
24. Dunn FL. Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 1990; 6: 47-61.
25. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34: 1255-1274.
26. Tato F, Vega GL, Tall AR, Grundy SM. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 112-120.
27. Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993; 99: 219-228.
28. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb 1991; 11: 797-804.
29. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BH, van Tol A et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in Type 2 diabetic and non-diabetic subjects: role of CETP and triglycerides. Diabetes 2005; 54: 3554-3559.
30. Herron KL, Vega-Lopez S, Conde K, Ramjiganesh T, Roy S, Shachter NS et al. Pre-menopausal women, classified as hypo- or hyperresponders, do not alter their LDL/HDL ratio following a high dietary cholesterol challenge. J Am Coll Nutr 2002; 21: 250-258.
31. Noone E, Roche HM, Black I, Tully AM, Gibney MJ. Effect of postprandial lipaemia and Taq1B polymorphism of the cholesteryl ester transfer protein (CETP) gene on CETP mass, activity, associated lipoproteins and plasma lipids. Br J Nutr 2000; 84: 203-209.
32. Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Atherosclerosis 1998; 141: 87-98.
33. Becker A, Bos G, de Vegt F, Kostense PJ, Dekker JM, Nypels G et al. Cardiovascular events in type 2 diabetes: comparison with non-diabetic individuals without and with prior cardiovascular disease. Ten-year follow-up of the Hoorn Study. Eur Heart J 2003; 24: 1406-1413.
34. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005; 36: 232-240.
35. Dekker JM, Girman C, Rhodes T, Nypels G, Stehouwer CD, Bouter LM et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666-673.
36. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93.
37. de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J Am Coll Cardiol 2004; 43: 854-857.
38. Boekholdt SM, Sacks FM, Jukema JW, Shephard J, Freeman DJ, McMahon AD et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005; 111: 278-287.
39. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219.